Yasser Farahat

Dr.Yasser Farahat,MD,FEBU,PhD,FRCS(Urol) Professor of Urology Consultant Endo-Urology & Minimally invasive Surgery Sheikh Khalifa Hospital,UAE EUS Head of Scientific Committee UAA past president SIU Vice President Chairman of Arab School of Urology

14th August 2025

Time Session
08:00
16:50
  • Sung Yong Cho Korea (Republic of) Speaker Robotic URS: Can It Really Improve Precision and Reduce Surgeon Fatigue?Use of AI and Robots in Endourology
  • Cheng-Chia LinTaiwan Speaker DISS plus FANS used in RIRSNew technologies and techniques are constantly emerging, but the most important part of our discussions is how to use them most effectively. Through this surgical demonstration, we hope to share the procedure and our experience with everyone.健保各領域審查共識及討論-結石
  • Abhay MahajanIndia Moderator
    Cheng-Chia LinTaiwan Moderator DISS plus FANS used in RIRSNew technologies and techniques are constantly emerging, but the most important part of our discussions is how to use them most effectively. Through this surgical demonstration, we hope to share the procedure and our experience with everyone.健保各領域審查共識及討論-結石
    Chong-Tsung WenSingapore Moderator Infection Complications after Stone Surgery
  • Yi Quan TanSingapore Speaker How Suction Changed My Hospital Practice of Flexible UreteroscopySuction in Endourology has truly been a gamechanger in recent years. In this talk, Dr Yi Quan Tan discusses how rapid technological advancements have evolved his hospital's practice of performing RIRS. Working alongside Dr Vineet Gauhar in the Endourology unit at Ng Teng Fong General Hospital in Singapore, Dr Tan provides a glimpse of how early adoption of new technology and concepts have helped push boundaries and improved RIRS outcomes for their patients.
  • Jaisukh KalathiaIndia Speaker Digitalization in Suction PCNL Can Change Practice
  • Han Kyu ChaeKorea (Republic of) Speaker Endoscopic Combined Intra Renal Surgery: New FrontiersBackground: Endoscopic Combined Intra Renal Surgery (ECIRS) has evolved as a versatile approach that combines the strengths of percutaneous nephrolithotomy (PCNL) and retrograde intrarenal surgery (RIRS), allowing for simultaneous anterograde and retrograde access. This dual approach has shown advantages in treating large or complex renal stones, including full or partial staghorn calculi, particularly in cases where monotherapy may be suboptimal. Objectives: This lecture will explore recent advancements in ECIRS, highlight regional practices in Asia, and propose future directions that may redefine the standard of care in endourology. Key Topics Covered: Technical evolution: From prone to modified supine position; advancement in ultra-mini PCNL and flexible ureteroscopy integration. Instrument synergy: Role of suction PCNL systems and navigable ureteroscopes in optimizing stone clearance and reducing operative time. Asian perspective: Surgical position, tract size, and imaging modality preferences vary across countries, reflecting diverse adaptations and innovations in ECIRS techniques. Clinical outcomes: Review of recent multicenter data showing ECIRS's impact on stone-free rates, complication reduction, and postoperative recovery. Future frontiers: Integration of AI-guided navigation, pressure-controlled irrigation systems, and 3D intraoperative imaging to refine intrarenal surgery. Conclusion: As endourological technology advances, ECIRS stands at the intersection of innovation and practicality. The next frontier lies not only in technical refinement but also in tailoring approaches to anatomical and cultural variability across Asia. This session aims to foster collaboration and knowledge sharing to drive further evolution in combined intrarenal stone surgery.
  • Chu Ann Chai Malaysia Speaker Navigating the Complex Renal Anatomy with FANS?
  • Boyke SoebhaliIndonesia Speaker Updates on Pharmacological Therapy for UrolithiasisUrolithiasis, a prevalent and recurrent urological condition, requires a multifaceted approach combining pharmacological, dietary, and surgical interventions. Recent advancements in pharmacological therapy emphasize personalized treatment based on stone composition, metabolic profiles, and patient-specific risk factors. For calcium oxalate stones, the most common type, thiazide diuretics remain first-line therapy to reduce urinary calcium excretion, while potassium citrate is recommended to increase urinary citrate levels, inhibiting stone formation. Dietary modifications, such as reduced oxalate intake and adequate calcium consumption, are adjunctive measures. In primary hyperoxaluria (PH), novel RNA interference (RNAi) agents like lumasiran and nedosiran significantly lower urinary oxalate levels, offering promising alternatives for patients unresponsive to pyridoxine. Uric acid stones are managed with urinary alkalinization using potassium citrate or sodium bicarbonate to maintain a pH >6.0, enhancing uric acid solubility. Xanthine oxidase inhibitors (allopurinol, febuxostat) are reserved for hyperuricemic patients. Cystine stones, though rare, require alkalinization and thiol-based drugs (tiopronin) to improve cystine solubility. Struvite stones, associated with urease-producing infections, necessitate antibiotics and urinary acidification (e.g., L-methionine) alongside surgical removal. Emerging therapies like theobromine show potential in inhibiting uric acid crystallization, while phytate demonstrates inhibitory effects on calcium salt aggregation. Medical expulsive therapy (MET) with alpha-blockers (tamsulosin) remains effective for distal ureteral stones (5–10 mm), reducing time to expulsion and need for surgery. However, MET efficacy diminishes for proximal stones or those >10 mm, necessitating surgical intervention. Future directions include optimizing RNAi therapies for hereditary stone diseases and integrating smartphone apps to enhance treatment adherence. A tailored, evidence-based approach combining pharmacological and lifestyle interventions is crucial for reducing recurrence and improving patient outcomes.Suction PCNL vs Suction RIRS? Do We Have a WinnerThe management of renal stones has evolved with the introduction of suction-assisted techniques in both percutaneous nephrolithotomy (PCNL) and retrograde intrarenal surgery (RIRS). Suction PCNL, including mini-PCNL and flexible mini-PCNL (F-mPCNL), utilizes negative pressure to improve stone clearance and reduce intrarenal pressure, while suction RIRS employs vacuum-assisted ureteral access sheaths (V-UAS) or direct in-scope suction (DISS) to enhance fragment removal and minimize infectious complications. Recent studies highlight that suction PCNL achieves superior stone-free rates (SFRs) in a single session, particularly for stones >2 cm, with SFRs ranging from 93.8% to 95.1% compared to 77.8%–87.9% for suction RIRS. However, suction RIRS offers advantages in reduced invasiveness, shorter hospital stays (1–3 days vs. 2–5 days for PCNL), and lower complication rates (e.g., bleeding, transfusion needs). For infectious stones, suction RIRS with V-UAS demonstrates lower postoperative infection markers (CRP, PCT) and fewer febrile complications than PCNL . Operative times vary, with suction PCNL often being faster for large stones (47–82 min) but requiring fluoroscopy, while suction RIRS avoids tract-related risks but may necessitate staged procedures for stones >2 cm. Cost-effectiveness analyses favor suction PCNL due to fewer retreatments, though RIRS reduces radiation exposure.
  • Q&A
  • Anil ShresthaNepal Moderator Clearpetra the Sheath of Choice for Lower Pole StonesSFR Assessment: Timing and Modalities
    Chinnakhet Ketsuwan Thailand Moderator Intra Renal Pressure Defines Outcomes: Current EvidenceIntrarenal pressure (IRP) is a crucial physiological parameter during endourological interventions, as elevated IRP is closely linked to increased fluid absorption, intrarenal backflow, compromised renal perfusion, and postoperative complications. Experimental studies in animal models have consistently demonstrated a correlation between increased IRP and augmented irrigation fluid absorption, renal parenchymal backflow, and reductions in renal blood flow. Clinical studies have reported baseline IRP values ranging from 14 to 17 mmHg, with transient peristaltic peaks reaching up to 25 mmHg. Notably, IRP frequently surpassed 60 mmHg during endoscopic procedures, particularly when utilizing manual hand-pump irrigation or employing ureteral access sheaths (UAS) with smaller diameters. Significant risk factors identified for sustained elevations of IRP include non-prestented ureters, Asian ethnicity, and omission of UAS placement. Furthermore, elevated IRPs have demonstrated a direct association with infectious adverse events, notably postoperative sepsis. Randomized controlled trials have established that manual hand-pump irrigation generates substantially higher IRPs compared to pressurized irrigation bags. Additionally, serial manual irrigation boluses have been shown to produce prolonged IRP elevations, with maximum peaks exceeding 100 mmHg and durations surpassing 40 seconds. Collectively, both preclinical and clinical evidence underscores the necessity of meticulous intraoperative IRP management during endourological procedures. Strategic optimization of irrigation techniques and appropriate UAS selection are imperative to effectively maintain IRP within safe physiological limits, thereby minimizing the risk of complicationsRole of VR/AR/MR in Endourology and Urolithiasis Renal stone disease is a common urological condition affecting diverse patient populations. Percutaneous nephrolithotomy (PCNL) is widely recognized as the primary treatment for large or complex renal calculi, offering high stone-free rates with low complication profiles. Nevertheless, achieving accurate percutaneous renal access (PCA) remains technically challenging due to anatomical proximity to vital structures and insufficient hands-on training opportunities for urologists. Virtual reality (VR) simulators, such as the PERC Mentor and Uro Mentor, have demonstrated significant improvements in PCA proficiency, operative efficiency, and complication reduction, establishing their validity as effective training platforms. Additionally, mixed reality (MR) and 3D holographic technologies, exemplified by HoloLens, enhance surgical planning and procedural accuracy, particularly in calyceal targeting during PCNL. Recent nationwide training needs assessments have further advocated for the integration of these advanced simulation technologies into urological education curricula. Ultimately, systematic incorporation of VR and MR simulation into residency training holds substantial promise in bridging existing skill gaps, refining surgical competencies, and circumventing ethical concerns associated with traditional methods of surgical education.
  • Mohamad Afzal Bin Farikhullah KhanMalaysia Speaker Thullium Fibre Laser: A Unique Laser for Urological Use
  • Takaaki InoueJapan Speaker New Advancement on Retrograde Intrarenal SurgeryRetrograde intrarenal surgery (RIRS) has dramatically grown up around world for stone management. Why has RIRS been getting popullar and increasing nowadays?. The reaseon are absoulutely "Technological development with collaborated engineering comapny" and " Global communicaton and collaboration in Endourology". Endourology has still been improving and expanding more and more. Thereby, many novel devices and machine are launching faster. We, urologists should catch up this faster trend and acquire these knowledge for our clinical use. However, most of urologists can not catch up it. Therefore, I will share you all these novel chage of mind and tech-knowledge of stone field in this session. Do We Need Augmented Reality for Renal Stone Management?What is Augmented reality and Vertual reality in medicine?. The paradigm shift of medicine which includes AI, Robotics, VR, and AR etc named Digital transformation has been still emerging. Of course, these shift is gradually permeating in stone field. Especially, in terms of VR, AR, we wonder if this kind of DX is useful in stone management. if so, how do we use it in clinical practice? Today, I will talk these future role in stone management, and expectation. Which Laser for RIRS: Pulsed Thulium YAG Laser We can use three kind of laser such as Holumium YAG, Thulium YAG, and Thulium fiber laser for stone management. Which lase are best option for stone patients? I will talk about featurs and advantage of pulsed-Thulium YAG laser. There are two kinds of p-Tm;YAG laser machine nowadays. P^Tm;YAG has unique characteristics as laser wave. Therefore, this laser would be able to use Stone, BPH, UTUC. Especially, p-Tm YAG laser can utilize for Stone ablation, fragmentingand and UTUC ablation, shock wave. We will share our experoence and thoughts. New Advancement on Retrograde Intrarenal Surgery
  • Albert El HajjLebanon Speaker Battle of the Robots in Flexible Ureteroscopy: What's the Verdict?AAU Lecture: Robotic Flexible Ureterorenoscopy— Gimmick or a True Helper? What’s It Cost Performance Value?
  • Jeremy TeohHong Kong, China Speaker Transurethral En Bloc Resection of Bladder Tumor: Where Are We Now?There is increasing evidence that transurethral en bloc resection of bladder tumour (ERBT) could lead to better peri-operative and oncological outcomes in patients with non-muscle-invasive bladder cancer. Modified approaches of ERBT have also been proposed to expand its indications for larger bladder tumours. The quality of resection is also the key for bladder-sparing treatment for muscle-invasive bladder cancer. We foresee an exciting journey ahead for ERBT, and as a urologist, we must embrace this novel technique for the best interest of our bladder cancer patients. To Publish or not to Publish? Navigating the path to academia in urologyDoing good science is the basis for technological advancement in healthcare. However, pursuing a path to academic in urology is often tough, stressful and frustrating. In this talk, I will share with you what I have learnt throughout my 15 years of research work. I will let you know what's the best and fastest way to become a globally renowned and successful researcher. Most importantly, I will explain what it takes to develop a great team and create a positive impact in people's lives. Believe in yourself! If I can do it, so can you.SIU Lecture: Role of MISTs in Male LUTS Surgical Management (Will TUR-P/ Laser Prostatectomy be Replaced?)Transurethral resection of prostate (TURP) is the current gold standard in treating patients with benign prostatic hyperplasia. Laser prostatectomy has also been used widely especially in patients who are on anticoagulants. However, both TURP and laser prostatectomy are associated with several problems including the need of spinal / general anaesthesia and the risk of male sexual dysfunction. In the past decade, we have witnessed the introduction of multiple new technologies including Rezum, Urolift, iTind and Aquablation. in this SIU lecture, we will discuss about the technical details, as well as the pros and cons of every new technology. We will also invite you to be our jury and decide whether TURP and laser prostatectomy will be replaced in the future. Novel Intravesical Therapeutics in the Evolving Landscape of NMIBCNon-muscle-invasive bladder cancer (NMIBC) is well known to be a difficult disease to manage, with a 1-year recurrence rate of up to 61% and 5-year recurrence rate of 78%. Despite the use of intravesical BCG therapy, NMIBC patients may still experience recurrence and develop what we call BCG-unresponsive NMIBC. Conventionally, we offer upfront radical cystectomy for patients with BCG-unresponsive NMIBC, however, this is an ultra-major surgery with significant risk of complications and could also lead to significant deterioration in quality of life in the long run. We are in urgent need for novel therapies to manage this difficult condition. In this lecture, we will discuss the evidence on the different novel intravesical therapies in treating BCG-unresponsive NMIBC. SIU Lecture: Role of MISTs in Male LUTS Surgical Management (Will TUR-P/ Laser Prostatectomy be Replaced?)
  • Hsiang-Ying LeeTaiwan Speaker Best Laser for UTUCManagement of Total Ureteral Avulsion during Ureteroscopy
  • Q&A
  • Albert El HajjLebanon Moderator Battle of the Robots in Flexible Ureteroscopy: What's the Verdict?AAU Lecture: Robotic Flexible Ureterorenoscopy— Gimmick or a True Helper? What’s It Cost Performance Value?
  • Anggie N. RahwantoIndonesia Speaker Impact of Ureteral Access Sheath on Kidney Stones before and after FANS
  • Azimjon TursunkulovUzbekistan Speaker How to Perform Supine PCNL in Pediatrics? Is It Different from Adults?Percutaneous nephrolithotomy (PCNL) is increasingly favored as a minimally invasive method for treating kidney stones, especially in the supine position, due to its benefits for anesthesia, ergonomics, and overall patient safety. However, when performing supine PCNL in children, urologists encounter distinct challenges that differ significantly from adult patients. In this presentation, we will discuss the key differences and specialized techniques required to successfully and safely perform supine PCNL in pediatric cases. Important considerations in pediatric patients include their smaller anatomical size, larger stone-to-kidney size ratios, increased sensitivity to fluid overload, and greater vulnerability to radiation exposure. Particular care is needed in patient positioning due to fewer clear anatomical landmarks, making precise ultrasound-guided kidney access crucial to minimize radiation and enhance accuracy. The use of specially designed miniaturized instruments is essential for pediatric procedures, alongside careful management of fluid to prevent complications. Drawing from extensive personal experience and evidence-based practices, this presentation will cover practical adjustments, such as optimal patient positioning, precise kidney puncture techniques, careful tract dilation, nephroscopic approaches, effective stone removal strategies, and tailored postoperative care. This presentation aims to provide attendees with practical insights and techniques to enhance their approach to supine PCNL in pediatric patients, supporting outcomes comparable to those achieved in adult cases.
  • Shemeem Kachereente VitaQatar Speaker ESWL for Ureteric Stones: Art of Achieving 100% Stone Free RateExtracorporeal Shock Wave Lithotripsy (ESWL) remains a valuable, non-invasive option for managing ureteric stones, despite growing preference for endoscopic approaches. In this talk, I will share insights from over 40,000 ESWL procedures performed at our center, with a focus on optimizing technique, patient selection, and procedural nuances that have allowed us to consistently achieve near-complete clearance rates—even for distal and impacted stones. Key points include: Understanding anatomical and technical factors that influence ESWL success Strategies to overcome limitations traditionally associated with ureteric stone location The role of stenting, pain control, and imaging in maximizing outcomes Real-world evidence demonstrating ESWL’s continued relevance in modern stone management This session aims to reignite interest in ESWL by presenting practical, reproducible methods that can raise clearance rates close to 100%, when done with precision and experience.
  • Hsiang-Ying LeeTaiwan Facilitator Best Laser for UTUCManagement of Total Ureteral Avulsion during Ureteroscopy
  • Yasser FarahatUnited Arab Emirates Speaker Single-Use Cysto-Nephro Scope in ECIRS/ PCNL
  • Vineet GauharSingapore Speaker Experimental and Real World Take Away Messages on DISSSuction in Renal Stone Treatment: DISS, FANS or Combined Procedure?Need of Future Endourology
  • Karl Marvin TanPhilippines Moderator Which Laser for RIRS: Holmium YAG Laser
  • Giorgio BozziniItaly Speaker The Power of Magneto and Vapour Tunnel in Holep
  • Sarvajit Biligere Singapore Speaker Take Home Messages to Prevent Bladder Neck Contracture in Enucleation
  • Joy CastilloPhilippines Moderator Advance Course of Urolithiasis & Technology, Company Sponsored SymposiumWith continuous innovations in endourology, particularly in the field of retrograde intrarenal surgery (RIRS), the role of intrarenal pressure (IRP) has emerged as a key factor influencing surgical outcomes. This session will delve into the growing body of evidence linking elevated IRP to complications such as postoperative infections, renal injury, and reduced stone-free rates. The symposium will also introduce a focused discussion on pressure management strategies during RIRS, highlighting the Tidor System—an advanced platform designed to monitor and regulate IRP in real time. By combining current evidence with practical solutions, this session aims to equip urologists with a deeper understanding of IRP’s clinical impact and how emerging technologies can enhance safety and efficacy in stone surgery.
    Steffi YuenHong Kong, China Moderator The Power of Powerbend in Management of Lower Pole and Complex StonesThe management of lower pole stones (LPS) and complex renal calculi remains one of the most challenging aspects of contemporary urolithiasis treatment, with the deflection capability of flexible ureteroscopes serving as the critical determinant of surgical success. Modern flexible ureteroscopes achieve impressive bidirectional deflection angles of 270° or even more, representing a significant advancement from earlier generation instruments. However, this “working deflection” capacity becomes substantially compromised when therapeutic instruments, such as laser fibers or stone baskets, are inserted through the working channel. The anatomical challenges of lower pole access, particularly steep infundibulopelvic angles, necessitate prolonged maximal deflection during lithotrispy that significantly increases the risk of ureteroscope damage and surgeon fatigability. Deflection deterioration is also directly proportional to instrument usage, with newer single-use scopes coming to the rescue. The introduction of flexible and navigable suction access sheaths (FANS) has revolutionized lower pole stone management allowing direct access to performing lithotriopsy and stone fragments retrieval, reducing the need for stone basket in stone relocation and fragment retrieval. Recent multicenter studies demonstrate comparable stone-free rates (<2mm) between lower pole and non-lower pole locations (96.6% vs 98.4%) when using FANS, with minimal complications and low reintervention rates. With current technological advancements, combined with improved surgical techniques and the strategic choice of single-use ureteroscopes with good deflection power, one can significantly achieve high stone-free rates with low infectious complications and reinterventions with FANS flexible ureteroscopy in the treatment of complex lower pole stones. FANs in Endourology: Finding the Best Combination with Lasers and Scopes for Optimal Outcomes
  • Chinnakhet Ketsuwan Thailand Speaker Intra Renal Pressure Defines Outcomes: Current EvidenceIntrarenal pressure (IRP) is a crucial physiological parameter during endourological interventions, as elevated IRP is closely linked to increased fluid absorption, intrarenal backflow, compromised renal perfusion, and postoperative complications. Experimental studies in animal models have consistently demonstrated a correlation between increased IRP and augmented irrigation fluid absorption, renal parenchymal backflow, and reductions in renal blood flow. Clinical studies have reported baseline IRP values ranging from 14 to 17 mmHg, with transient peristaltic peaks reaching up to 25 mmHg. Notably, IRP frequently surpassed 60 mmHg during endoscopic procedures, particularly when utilizing manual hand-pump irrigation or employing ureteral access sheaths (UAS) with smaller diameters. Significant risk factors identified for sustained elevations of IRP include non-prestented ureters, Asian ethnicity, and omission of UAS placement. Furthermore, elevated IRPs have demonstrated a direct association with infectious adverse events, notably postoperative sepsis. Randomized controlled trials have established that manual hand-pump irrigation generates substantially higher IRPs compared to pressurized irrigation bags. Additionally, serial manual irrigation boluses have been shown to produce prolonged IRP elevations, with maximum peaks exceeding 100 mmHg and durations surpassing 40 seconds. Collectively, both preclinical and clinical evidence underscores the necessity of meticulous intraoperative IRP management during endourological procedures. Strategic optimization of irrigation techniques and appropriate UAS selection are imperative to effectively maintain IRP within safe physiological limits, thereby minimizing the risk of complicationsRole of VR/AR/MR in Endourology and Urolithiasis Renal stone disease is a common urological condition affecting diverse patient populations. Percutaneous nephrolithotomy (PCNL) is widely recognized as the primary treatment for large or complex renal calculi, offering high stone-free rates with low complication profiles. Nevertheless, achieving accurate percutaneous renal access (PCA) remains technically challenging due to anatomical proximity to vital structures and insufficient hands-on training opportunities for urologists. Virtual reality (VR) simulators, such as the PERC Mentor and Uro Mentor, have demonstrated significant improvements in PCA proficiency, operative efficiency, and complication reduction, establishing their validity as effective training platforms. Additionally, mixed reality (MR) and 3D holographic technologies, exemplified by HoloLens, enhance surgical planning and procedural accuracy, particularly in calyceal targeting during PCNL. Recent nationwide training needs assessments have further advocated for the integration of these advanced simulation technologies into urological education curricula. Ultimately, systematic incorporation of VR and MR simulation into residency training holds substantial promise in bridging existing skill gaps, refining surgical competencies, and circumventing ethical concerns associated with traditional methods of surgical education.
  • Ponco BirowoIndonesia Speaker Pressure Management Strategy in RIRS using Tidor System
  • Sung Yong Cho Korea (Republic of) Moderator Robotic URS: Can It Really Improve Precision and Reduce Surgeon Fatigue?Use of AI and Robots in Endourology
    Vineet GauharSingapore Moderator Experimental and Real World Take Away Messages on DISSSuction in Renal Stone Treatment: DISS, FANS or Combined Procedure?Need of Future Endourology
  • Steffi YuenHong Kong, China Speaker The Power of Powerbend in Management of Lower Pole and Complex StonesThe management of lower pole stones (LPS) and complex renal calculi remains one of the most challenging aspects of contemporary urolithiasis treatment, with the deflection capability of flexible ureteroscopes serving as the critical determinant of surgical success. Modern flexible ureteroscopes achieve impressive bidirectional deflection angles of 270° or even more, representing a significant advancement from earlier generation instruments. However, this “working deflection” capacity becomes substantially compromised when therapeutic instruments, such as laser fibers or stone baskets, are inserted through the working channel. The anatomical challenges of lower pole access, particularly steep infundibulopelvic angles, necessitate prolonged maximal deflection during lithotrispy that significantly increases the risk of ureteroscope damage and surgeon fatigability. Deflection deterioration is also directly proportional to instrument usage, with newer single-use scopes coming to the rescue. The introduction of flexible and navigable suction access sheaths (FANS) has revolutionized lower pole stone management allowing direct access to performing lithotriopsy and stone fragments retrieval, reducing the need for stone basket in stone relocation and fragment retrieval. Recent multicenter studies demonstrate comparable stone-free rates (<2mm) between lower pole and non-lower pole locations (96.6% vs 98.4%) when using FANS, with minimal complications and low reintervention rates. With current technological advancements, combined with improved surgical techniques and the strategic choice of single-use ureteroscopes with good deflection power, one can significantly achieve high stone-free rates with low infectious complications and reinterventions with FANS flexible ureteroscopy in the treatment of complex lower pole stones. FANs in Endourology: Finding the Best Combination with Lasers and Scopes for Optimal Outcomes
  • Manint UsawachintachitThailand Speaker What I Need as a Clinician in Single Use ScopesSpecial Consideration in Pediatric Endourology
  • Boyke SoebhaliIndonesia Moderator Updates on Pharmacological Therapy for UrolithiasisUrolithiasis, a prevalent and recurrent urological condition, requires a multifaceted approach combining pharmacological, dietary, and surgical interventions. Recent advancements in pharmacological therapy emphasize personalized treatment based on stone composition, metabolic profiles, and patient-specific risk factors. For calcium oxalate stones, the most common type, thiazide diuretics remain first-line therapy to reduce urinary calcium excretion, while potassium citrate is recommended to increase urinary citrate levels, inhibiting stone formation. Dietary modifications, such as reduced oxalate intake and adequate calcium consumption, are adjunctive measures. In primary hyperoxaluria (PH), novel RNA interference (RNAi) agents like lumasiran and nedosiran significantly lower urinary oxalate levels, offering promising alternatives for patients unresponsive to pyridoxine. Uric acid stones are managed with urinary alkalinization using potassium citrate or sodium bicarbonate to maintain a pH >6.0, enhancing uric acid solubility. Xanthine oxidase inhibitors (allopurinol, febuxostat) are reserved for hyperuricemic patients. Cystine stones, though rare, require alkalinization and thiol-based drugs (tiopronin) to improve cystine solubility. Struvite stones, associated with urease-producing infections, necessitate antibiotics and urinary acidification (e.g., L-methionine) alongside surgical removal. Emerging therapies like theobromine show potential in inhibiting uric acid crystallization, while phytate demonstrates inhibitory effects on calcium salt aggregation. Medical expulsive therapy (MET) with alpha-blockers (tamsulosin) remains effective for distal ureteral stones (5–10 mm), reducing time to expulsion and need for surgery. However, MET efficacy diminishes for proximal stones or those >10 mm, necessitating surgical intervention. Future directions include optimizing RNAi therapies for hereditary stone diseases and integrating smartphone apps to enhance treatment adherence. A tailored, evidence-based approach combining pharmacological and lifestyle interventions is crucial for reducing recurrence and improving patient outcomes.Suction PCNL vs Suction RIRS? Do We Have a WinnerThe management of renal stones has evolved with the introduction of suction-assisted techniques in both percutaneous nephrolithotomy (PCNL) and retrograde intrarenal surgery (RIRS). Suction PCNL, including mini-PCNL and flexible mini-PCNL (F-mPCNL), utilizes negative pressure to improve stone clearance and reduce intrarenal pressure, while suction RIRS employs vacuum-assisted ureteral access sheaths (V-UAS) or direct in-scope suction (DISS) to enhance fragment removal and minimize infectious complications. Recent studies highlight that suction PCNL achieves superior stone-free rates (SFRs) in a single session, particularly for stones >2 cm, with SFRs ranging from 93.8% to 95.1% compared to 77.8%–87.9% for suction RIRS. However, suction RIRS offers advantages in reduced invasiveness, shorter hospital stays (1–3 days vs. 2–5 days for PCNL), and lower complication rates (e.g., bleeding, transfusion needs). For infectious stones, suction RIRS with V-UAS demonstrates lower postoperative infection markers (CRP, PCT) and fewer febrile complications than PCNL . Operative times vary, with suction PCNL often being faster for large stones (47–82 min) but requiring fluoroscopy, while suction RIRS avoids tract-related risks but may necessitate staged procedures for stones >2 cm. Cost-effectiveness analyses favor suction PCNL due to fewer retreatments, though RIRS reduces radiation exposure.
    Takaaki InoueJapan Moderator New Advancement on Retrograde Intrarenal SurgeryRetrograde intrarenal surgery (RIRS) has dramatically grown up around world for stone management. Why has RIRS been getting popullar and increasing nowadays?. The reaseon are absoulutely "Technological development with collaborated engineering comapny" and " Global communicaton and collaboration in Endourology". Endourology has still been improving and expanding more and more. Thereby, many novel devices and machine are launching faster. We, urologists should catch up this faster trend and acquire these knowledge for our clinical use. However, most of urologists can not catch up it. Therefore, I will share you all these novel chage of mind and tech-knowledge of stone field in this session. Do We Need Augmented Reality for Renal Stone Management?What is Augmented reality and Vertual reality in medicine?. The paradigm shift of medicine which includes AI, Robotics, VR, and AR etc named Digital transformation has been still emerging. Of course, these shift is gradually permeating in stone field. Especially, in terms of VR, AR, we wonder if this kind of DX is useful in stone management. if so, how do we use it in clinical practice? Today, I will talk these future role in stone management, and expectation. Which Laser for RIRS: Pulsed Thulium YAG Laser We can use three kind of laser such as Holumium YAG, Thulium YAG, and Thulium fiber laser for stone management. Which lase are best option for stone patients? I will talk about featurs and advantage of pulsed-Thulium YAG laser. There are two kinds of p-Tm;YAG laser machine nowadays. P^Tm;YAG has unique characteristics as laser wave. Therefore, this laser would be able to use Stone, BPH, UTUC. Especially, p-Tm YAG laser can utilize for Stone ablation, fragmentingand and UTUC ablation, shock wave. We will share our experoence and thoughts. New Advancement on Retrograde Intrarenal Surgery
  • Anil ShresthaNepal Speaker Clearpetra the Sheath of Choice for Lower Pole StonesSFR Assessment: Timing and Modalities
  • Deepak Ragoori India Speaker How to Use Clearpetra Shetah to Minimize Post Operative Stenting after FANS
TICC - 2F 201DE

15th August 2025

Time Session
08:30
10:00
  • John DenstedtCanada Speaker UAA Lecture: Innovations in Renal Stone SurgeryInnovations in Renal Stone Surgery John Denstedt MD FRCSC Professor of Urology Schulich School of Medicine and Dentistry Department of Surgery Western University London Canada Recent years have seen a burst of innovation in techniques for minimally invasive treatment of renal stones. Current guidelines recommend either shock wave lithotripsy or retrograde intrarenal surgery {RIRS} for stones smaller than 2cm and percutaneous renal stone removal for calculi greater than 2cm in maximal diameter. Progress in mini percutaneous stone removal {mPCNL} has facilitated expansion of antegrade techniques to stones smaller than 2cm while concurrently RIRS has seen indications expand to include larger stones than previously considered. Most randomized trials have demonstrated similar operating times, hospital stays and complications comparing RIRS and MPCNL however stone free rates are generally documented to be improved with a percutaneous approach. Technology continues to advance and the development of flexible deflectable ureteral access sheaths with suction capability offer the possibility of improved stone free rates with RIRS while also decreasing intrarenal pressure, thus reducing the incidence of sepsis and other complications. This is challenging the traditional concept of limiting retrograde ureteroscopy to stones less than 2cm in diameter. This lecture will review the current literature on RIRS for intrarenal stones greater than 2cm, outlining expectations for the main parameters of stone free rate, complications and operating efficiency. Currently available technology and techniques will be presented allowing participants to take practical tips and tricks back to day to day urologic practice.
  • Yasser FarahatUnited Arab Emirates Moderator Single-Use Cysto-Nephro Scope in ECIRS/ PCNL
    Allen W. ChiuTaiwan Speaker Reflecting on the Past, Shaping the Present, and Envisioning the Future of UAASince 1990, the Urological Association of Asia (UAA) has stood as a beacon of collaboration, innovation, and advancement in urology in Asia. As we reflect on its evolution, acknowledge its current impact, and envision its future, it becomes clear that the UAA has played - and will continue to play - a pivotal role in shaping urological care, education, and research throughout Asia. Reflecting on the path we’ve traveled together from 16 member associations and 1,000 individual members in 2014 to 28 member associations and over 4,500 individual members today - I see more than growth. I see unity, commitment, and a shared belief in something bigger than ourselves. A defining milestone was enrolling the Urological Society of Australia and New Zealand into the UAA, further enriching our diversity and strengthening our position as a truly Asia-Pacific organization. The UAA proudly supports several journals, including the International Journal of Urology, the Indian Journal of Urology, Asian Urology, which continue to shape the academic discourse. The Asian Urological Resident Course (AURC) started in 2014, in collaboration with the American Urological Association, has become a cornerstone in nurturing clinical excellence among young urologists. The Young Leadership Forum, since 2012, developed in partnership with the European Urological Association, has fostered cross-continental mentorship and exchange. These initiatives symbolize our commitment to creating a future shared across borders. We have faced challenges under the impact of COVID-19, but conquered it with resilience and shared purpose. As healthcare needs evolve and patient expectations rise, the UAA aims to: 1. Promote regional research 2. Enhance training and education 3. Strengthen partnerships 4. Champion equity in healthcare.Complex Robotic Assisted Surgery for Urinary Fistula RepairRobotic-assisted (da Vinci) surgery is increasingly used for repair of urinary fistulas, including vesicovaginal, ureterovaginal, and enterovesical fistula. It offers a minimally invasive alternative to open surgery. A case report described using the da Vinci X system to fix a vesicovaginal fistula (VVF) post-hysterectomy in 105 min with no complications, a 2 day hospital stay, and excellent patient reported quality-of-life at 12 months. A literature review including 30 cases showed robotic repair of VVF reduced blood loss and shortened hospital stays by 2 days compared to open repair. A review found that robotic repair of complex urinary fistulas is technically feasible in expert hands, with good early outcomes and less morbidity than open techniques. This presentation illustrated the key operative procedures, inlcuding ureteral catheter placement to identify the ureteral tract, anchoring stitches on opened urinary bladder wall, robotic excision of the fistula tract, layered closure of bladder wall and adjacent organ (vagina or colon), with or without Interposition of tissue flaps (e.g. omentum or peritoneal flaps) to reinforce repair. The robot provides precise and secure ileal isolation with ICG technique for the ileal isolation, and and intracorporeal anastomosis to ureter and urinary bladder are safe. Intracorporeal bowel re-anastomosis and accessibility of the da Vinci platform is becoming more popular. The isolated ileal technique provides good urinary reconstruction (e.g., Neobladder, Augmentation Cystoplasty Ileal conduit (Bricker’s procedure), Orthotopic neobladder (Studer, Hautmann, etc.) The Role of the robot to harvestest, detubularize, and fold ileum to form bladder substitute. Suture to urethra and ureters. It is often performed entirely intracorporeally with the da Vinci Xi system.
  • Shin EgawaJapan Moderator
    Arnulf StenzlGermany Speaker EAU Lecture: AI to Support Informed Decision Making (INSIDE) for Improved Literature Analysis in Oncology.Robot-Assisted Radical Cystectomy and Intracorporeal Neobladder Formation
  • Stephen A. BoorjianUnited States Speaker AUA Lecture: 2025 Update of AUA and EAU NMIBC GuidelinesBoth the American Urological Association (AUA) and European Association of Urology (EAU) have developed guidelines for the management of non-muscle invasive bladder cancer (NMIBC). While subtle differences in several aspects of these guidelines exist which merit mentioning, both guidelines emphasis the concept of risk stratification. In particular, understanding the criteria which classifies patients with NMIBC as high risk avoids undertreatment of the patients most likely to experience disease progress. Likewise, recognizing the indications for cystectomy among high risk NMIBC patients is critical to optimize survival. Meanwhile, continued options emerge for patients classified as having BCG unresponsive NMIBC, such that knowledge of that definition as well as current management strategies for these patients facilitates contemporary practice.From Bench to Bedside - A Comprehensive Overview of Kidney CancerEvaluation of patients with a newly identified renal mass includes dedicated cross-sectional imaging for appropriate characterization. Genetic syndromes which include renal cell carcinoma (RCC) are increasingly understood, and indeed knowledge of the intracellular pathways of these conditions has facilitate rationale drug development for kidney cancer. Managing patients with a small renal mass involves a critical assessment of competing risks inherent to the tumor, the patient (underlying comorbidity status), and the proposed treatment. Renal mass biopsy may play a role in select cases for additional information/risk stratification. The safety of active surveillance is being increasingly demonstrated as longer-term follow-up matures. Meanwhile, select patients with high risk disease now have the option of adjuvant immunotherapy following surgical resection. In the setting of metastatic RCC, again risk stratification plays a critical role in the decision for – and timing of – cytoreductive nephrectomy, particularly in the contemporary era of checkpoint inhibitor therapies.Real World Experience in the Management of Upper Tract Urothelial CarcinomaThe biggest challenging in managing upper tract urothelial carcionma (UTUC) remains accurate staging of tumors at diagnosis. Given the limited ability of contemporary staging methods, clinical risk stratification models have been developed to assist in providing risk-based treatment recommendations. For example, endoscopic management (e.g., ablation) represents the recommended first line approach for patients with low risk disease. Importantly, follow-up for these patients should include endoscopic re-evaluation. The value of testing patients with UTUC for Lynch syndrome is also critical to recognize. A role for neoadjuvant chemotherapy is being increasing explored for patients classified with high-risk UTUC, while several options exist for adjuvant chemotherapy and immunotherapy for patients with adverse pathology at surgical resection. Continued investigation into prevention of postoperative intravesical recurrences in patients with UTUC is warranted given the frequency of metachronous tumor development in the bladder among these patients.Updates on MIBC and Advanced Bladder Cancer: Where do We Stand in 2025While neoadjuvant chemotherapy prior to radical cystectomy has been demonstrated with randomized trial data to improve survival for patients undergoing radical cystectomy, nevertheless utilization is often restricted by misunderstandings regarding patient eligibility factors. As such, defining eligibility criteria will facilitate increased adoption. Likewise, new data indicates a role for adjust immunotherapy in select patients following surgery as well. Moreover, important recent evidence on the role of extended lymph node dissection and the opportunities for preserving sexual function after cystectomy by modifying surgical technique are critical to review in order to optimize future patient outcomes. Further, recent advancements in systemic therapy options for patients with metastatic urothelial carcinoma have led to unprecedented survival rates.Revisit on Testicular Tumors-What we Learned from past and Prepared for the FutureGerm cell tumor (GCT) progression typically occurs in a predictable sequence of disease spread to the retroperitoneum first and then distant metastases. Understanding the role of serum tumor markers at various disease stages is critical for guideline-concordant management and to optimize patient outcomes, avoiding both undertreatment and overtreatment. For patients with seminoma, retroperitoneal lymph node dissection now represents an option for patients with low volume retroperitoneal lymph node disease, with the goal of avoiding the long-term toxicities associated with chemotherapy and radiotherapy. For patients with residual postchemotherapy masses in seminoma, increasing evidence suggests that PET scans should be utilized/interpreted with caution, and that in the absence of mass growth continued follow-up may be the strategy for most patients. Similarly, for patients with nonseminomatous GCTs (NSGCT) and equivocal retroperitoneal lymph nodes at presentation, re-scanning after an interval of approximately 6-8 weeks may be preferable to initial treatment, as many of these nodes represent benign processes and as such will resolve. Nevertheless, postchemotherapy retroperitoneal lymph node dissection remains a critical component of the management of patients with NSCGT and a residual mass. Risk Stratification and Contemporary Management of Biochemical RecurrenceBiochemical recurrence (BCR) has been reported in up to 35% of patients following radical prostatectomy. Understanding the natural history and clinicopathologic risk factors associated with disease progression is critical to facilitate an individualized treatment approach. Likewise, recognizing the details of treatment delivery with salvage radiotherapy is necessary to optimize outcomes. Further, as data emerge on the utilization of systemic therapy for non-metastatic BCR, being able to contextualize reported outcomes with patient age, comorbidity status, and disease risk will enhance appropriate care delivery.
  • Bannakij LojanapiwatThailand Moderator PSA Kinetics Following PADT in mHSPC. Is It a Real-World Tool for Predicting Oncologic Outcome?PSA Kinetics following Primary Androgen Deprivation Therapy (PADT) in mHSPC. Is it a Real-world Tool for Prediction Oncologic Outcome? Bannakij Lojanapiwat, M.D. Professor of Urology, Chiang Mai University, Thailand. Of recent guidelines, upfront primary androgen deprivation monotherapy or combination therapy (PADT) is recommended for the treatment of metastatic hormone sensitive prostate cancer (mHSPC). Limitation of real-world treatment such as culture difference, financial barrier, geographic access to treatment and high operation/ radiation risks associated with medical comorbidity led to underutilization of combination therapy as the standard guideline. Prognostic factors are important in clinical practice which can predict the clinical outcome that offer the pre-treatment counseling for patients to select the optimal treatment. Prostate specific antigen (PSA) levels is one of the important key prognostic markers. PSA kinetics of nadir PSA level and time to nadir PSA following the treatment are the important role for progression to CRPC and oncologic outcome. Our study and the previous studies reported better oncologic outcome especially overall survival, cancer specific survival and time to developed CRPC in mHSPC patients received upfront PADT who decline PSA≥95% (deep responder), PSA nadir ≤ 0.2 ng/ml (low PSA nadir level), time to PSA nadir ≥ 6 month and PSA decline velocity <11 ng/ml/month. PSA Kinetics following Primary Androgen Deprivation Therapy (PADT) is one of a real-world tool for prediction oncologic outcome in the treatment of mHSPC.
    David PensonUnited States Speaker Comparison of Various Treatment Options for Localized Prostate CancerThere are numerous therapeutic strategies used to treat localized prostate cancer, each with unique advantages and disadvantages. Furthermore, prostate cancer itself is heterogeneous with some tumors being indolent and others being more aggressive. We will from the presentation by looking at outcomes separately in patients with favorable prognosis and those with unfavorable prognosis, based upon baseline clinical characteristics. We will first compare cancer control and mortality outcomes amongst the various options. We will then present data on patient-reported outcomes. At the conclusion of the presentation, attendees will have a better understanding of outcomes following treatment for localized prostate cancer and will be better prepared to counsel patients newly diagnosed with this common malignancy.Updates on Combination Therapy for Advanced Prostate CancerOver the past decade, there are have been significant advances in the treatment of metastatic prostate cancer. Randomized clinical trial data have demonstrated that combination therapies are superior to monotherapy in terms of cancer control and survival. Various treatment options will be discussed for metastatic castrate-sensitive and -resistant prostate cancer. These will be compared in terms of efficacy and side effect profiles to aid in treatment selection in this The Startup of An Academic Urologist - How to Build up Your Team in Clinical ResearchMany young academic urologists wish to perform clinical research at their institution. Often, however, this is challenging due to lack of resources or time. In this presentation, we will discuss how to build a clinical research program, including identifying what types of individuals need to be part of the team and what sort of resources are required for success. While American examples will often be used, information from this presentation will still be applicable globally.A Programmatic Approach to Prostate Cancer ScreeningProstate cancer screening has advanced beyond annual PSA testing. We now have numerous tools available to aid in identifying men at risk for harboring clinically significant prostate cancer, including MRI and various novel biomarkers. In this presentation, we will review these modalities and lay out a systematic approach to screening in 2025.
  • Ponco BirowoIndonesia Moderator Pressure Management Strategy in RIRS using Tidor System
    Declan MurphyAustralia Speaker PSMA PET Scan in Diagnosing Early/Advanced Localized Prostate Cancer Especially Comparing Various Radioactive Tracers
TICC - 3F Plenary Hall